← Leaderboards
Gulam Abbas Manji
Columbia University Health Sciences
$3,748,789
Attributed
$7,497,578
Total exposure
3
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2017–25$2M$1.5M$1M$500K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,591,748 · 2
FDA$1,905,830 · 1
By mechanism
U01$3,892,796 · 1
R01$3,604,782 · 2
Top collaborators
- Kenneth P Olive7 shared
- Gary K Schwartz4 shared
Most similar at Columbia University Health Sciences
Same institution · by research overlap
- Kenneth P Olive$11,212,298
- Anil K Rustgi$51,275,906
- Krzysztof Kiryluk$17,737,105
- Chunhua Weng$15,667,890
- George M. Hripcsak$48,919,189
Others in their field
Other Emerging Leaders on “Malignant Neoplasm Of Pancreas”
- Kian H Lim · Washington University$6,946,469
- Costas Andreas Lyssiotis · University Of Michigan At Ann Arbor$6,921,511
- Yi Ye · New York University$6,186,890
- William Andrew Daunch · Focal Medical, Inc.$6,184,629
- Christine Iok In Chio · Columbia University Health Sciences$5,403,170
- Vinod P Balachandran · Sloan-Kettering Inst Can Research$5,168,008
Research focus
Malignant Neoplasm Of PancreasPancreasImmunosuppressionMalignant Epithelial CellMalignant NeoplasmsOlives - DietaryFibroblastsHeterogeneityInnovationKpc ModelBiological ModelsComplexMouse ModelMutantCytotoxic ChemotherapyCancer CellGenetically Engineered MouseCell TypeImmunotherapyInhibitorClinical TrialsInvestigationCellsPancreatic Ductal Adenocarcinoma
Grant awards (11)
Elucidation and targeting of paracrine cascades in PDAC$985,518
U01 · FY2025 · CA
Targeting cell regulatory states to complement MEK/autophagy inhibition in pancreatic cancer$582,311
R01 · FY2025 · CA
Elucidation and targeting of paracrine cascades in PDAC$936,242
U01 · FY2024 · CA
Targeting cell regulatory states to complement MEK/autophagy inhibition in pancreatic cancer$552,526
R01 · FY2024 · CA
Elucidation and targeting of paracrine cascades in PDAC$985,518
U01 · FY2023 · CA
Targeting cell regulatory states to complement MEK/autophagy inhibition in pancreatic cancer$564,115
R01 · FY2023 · CA
Phase 2 study of combination therapy with PLX3397 and sirolimus to target tumor-associated macrophages in malignant peripheral nerve sheath tumors$405,830
R01 · FY2023 · FD · contact PI
Elucidation and targeting of paracrine cascades in PDAC$985,518
U01 · FY2022 · CA
Phase 2 study of combination therapy with PLX3397 and sirolimus to target tumor-associated macrophages in malignant peripheral nerve sheath tumors$500,000
R01 · FY2021 · FD · contact PI
Phase 2 study of combination therapy with PLX3397 and sirolimus to target tumor-associated macrophages in malignant peripheral nerve sheath tumors$500,000
R01 · FY2020 · FD · contact PI
Phase 2 study of combination therapy with PLX3397 and sirolimus to target tumor-associated macrophages in malignant peripheral nerve sheath tumors$500,000
R01 · FY2017 · FD · contact PI